{"schema_version":"1.0","type":"article","title":"又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代","url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras.md","lang":"zh-Hant","date":"2026-07-17","publish_at":"2026-07-17T01:46:13.333Z","updated_at":"2026-07-17","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","Revolution Medicines","RevMed","胰臟癌","KRAS G12D","RAS(ON)","Zoldonrasib","Daraxonrasib","ESMO GI 2026","臨床數據","組合療法","腫瘤"],"summary":"Daraxonrasib 已用第三期總生存期資料抬高胰臟癌 RAS 賽道門檻；zoldonrasib 與 pan-RAS 或化療的早期組合訊號，則把競爭從單藥推向治療生態系。","key_points":[],"facts":[],"sections":["01｜為什麼胰臟癌這麼難？KRAS 是關鍵開關","02｜Zoldonrasib 加 Daraxonrasib：不是 1+1，而是「深度＋廣度」","03｜資料真的強，但還不能忘記它仍是早期樣本","04｜RevMed 正在做的，是把 RAS 做成一個 franchise","05｜國際玩家都會重新被定價","結語｜癌王沒有被終結，但治療邏輯真的變了","參考資料"],"references":[{"title":"[Revolution Medicines","source":"Phase 1/2 clinical data for zoldonrasib combination regimens, 2026-07-02]","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-presents-phase-12-clinical-data-zoldonrasib"},{"title":"[ClinicalTrials.gov","source":"RASolute 302: daraxonrasib versus investigator's choice in previously treated metastatic PDAC (NCT06625320)]","date":"","url":"https://clinicaltrials.gov/study/NCT06625320"},{"title":"[Revolution Medicines","source":"RASolute 302 ASCO plenary presentation and overall-survival results]","date":"","url":"https://ir.revmed.com/node/13046/pdf"},{"title":"[ClinicalTrials.gov","source":"Zoldonrasib phase 1/1b study (NCT06040541)]","date":"","url":"https://clinicaltrials.gov/study/NCT06040541"},{"title":"[ClinicalTrials.gov","source":"RASolute 305 first-line phase 3 study (NCT07621718)]","date":"","url":"https://clinicaltrials.gov/study/NCT07621718"},{"title":"[Revolution Medicines","source":"First-quarter 2026 corporate and pipeline update]","date":"","url":"https://ir.revmed.com/node/12976/pdf"},{"title":"[ClinicalTrials.gov","source":"MRTX1133 study in advanced solid tumors with KRAS G12D mutation (NCT05737706)]","date":"","url":"https://clinicaltrials.gov/study/NCT05737706"},{"title":"[ClinicalTrials.gov","source":"LY4066434 study in KRAS-mutant solid tumors (NCT06607185)]","date":"","url":"https://clinicaltrials.gov/study/NCT06607185"}],"images":[{"alt":"胰臟癌中的 KRAS G12D 分子開關與下游訊號路徑","url":"https://drugnews.com.tw/assets/articles/revmed-ras/facebook-01.webp"},{"alt":"Zoldonrasib 與 daraxonrasib 從突變深度與逃脫路徑廣度形成 RAS 雙封鎖","url":"https://drugnews.com.tw/assets/articles/revmed-ras/facebook-02.webp"},{"alt":"ESMO GI 2026 公布的 zoldonrasib 與 daraxonrasib 組合療法早期臨床訊號","url":"https://drugnews.com.tw/assets/articles/revmed-ras/facebook-03.webp"},{"alt":"RevMed 以 daraxonrasib 為骨架建立多突變、多治療線與多組合的 RAS 產品矩陣","url":"https://drugnews.com.tw/assets/articles/revmed-ras/facebook-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/revmed-ras/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-17）。又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代。https://drugnews.com.tw/articles/2026-07-17-revmed-ras.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-17-revmed-ras-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}